Yoon-Koo Kang

Yoon-Koo Kang has made seminal contributions to gastric cancer clinical trials, co-leading the REGARD trial that established ramucirumab as the first biologic agent to demonstrate survival benefit as a second-line single agent for advanced gastric or GEJ adenocarcinoma. His research on the RAINBOW trial further established ramucirumab plus paclitaxel as the standard second-line regimen for advanced gastric cancer with superior overall survival compared to paclitaxel alone. He contributed to the ToGA trial establishing trastuzumab plus chemotherapy for HER2-positive advanced gastric cancer and has investigated multiple subsequent HER2-targeted and checkpoint immunotherapy combinations in Korean and global gastric cancer populations. His leadership of Korean gastric cancer clinical trial networks has generated foundational evidence that has shaped global treatment guidelines for advanced gastric cancer.